IGF2 Protein (AA 25-91) (AVI tag,Fc Tag,Biotin)

Catalog No. ABIN4949023

Product Details

Target: IGF2 (Insulin-Like Growth Factor 2 (IGF2))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 25-91

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This IGF2 protein is labelled with AVI tag,Fc Tag,Biotin.

Application: Functional Studies (Func)

Brand: MABSol®,PrecisionAvi

Sequence: AA 25-91

Specificity: Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Characteristics: This protein carries an Avi tag (Avitag™) at the N-terminus, followed by a human IgG1 Fc tag. The protein has a calculated MW of 35.4 kDa. As a result of glycosylation, the protein migrates as 40 kDa under reducing (R) condition, and 66 kDa under non-reducing (NR) condition (SDS-PAGE).

Purity: >95 % as determined by SDS-PAGE.

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Comment:

Ready-to-use AvitagTM biotinylated protein:
The product is exclusively produced using the AvitagTM technology. Briefly, a unique 15 amino acid peptide, the Avi tag, is introduced into the recombinant protein during expression vector construction. The single lysine residue in the Avi tag is enzymatically biotinylated by the E. Coli biotin ligase BirA.

This single-point enzymatic labeling technique brings many advantages for commonly used binding assays. The biotinylation happens on the lysine residue of Avi tag, and therefore does NOT interfere with the target protein's natural binding activities. In addition, when immobilized on an avidin-coated surface, the protein orientation is uniform because the position of the Avi tag in the protein is precisely controlled.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Tris with Glycine, Arginine and NaCl,  pH 7.5

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Target Details

Target: IGF2 (Insulin-Like Growth Factor 2 (IGF2))

Alternative Name: IGF-II (IGF2 Products)

Synonyms: C11orf43 Protein, IGF-II Protein, PP9974 Protein, LOC100136550 Protein, igf2 Protein, igf2b Protein, wu:fc26e03 Protein, zgc:91781 Protein, igf-2 Protein, insigf Protein, pp9974 Protein, AL033362 Protein, Igf-2 Protein, Igf-II Protein, M6pr Protein, Mpr Protein, Peg2 Protein, IGFII Protein, RNIGF2 Protein, IGF-II-B Protein, igf2-a Protein, igf2-b Protein, insulin like growth factor 2 Protein, insulin-like growth factor II Protein, insulin-like growth factor 2a Protein, insulin like growth factor 2 S homeolog Protein, insulin-like growth factor 2 Protein, insulin-like growth factor 2 (somatomedin A) Protein, insulin like growth factor 2 L homeolog Protein, IGF2 Protein, LOC100136550 Protein, igf2a Protein, igf2.S Protein, Igf2 Protein, igf2.L Protein

Background: Insulin-like growth factor 2 (IGF-2) is also known as Somatomedin-A, IGF-II, PP9974, and is one of three protein hormones that share structural similarity to insulin. IGF-2 exerts its effects by binding to the IGF-1 receptor. IGF2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signalling antagonist, that is, to prevent IGF2 responses. The major role of IGF2 is as a growth promoting hormone during gestation. In the process of Folliculogenesis, IGF2 is created by Theca cells to act in an autocrine manner on the theca cells themselves, and in a paracrine manner on Granulosa cells in the ovary. IGF2 promotes granulosa cell proliferation during the follicular phase of the menstrual cycle, acting alongside Follicle Stimulating Hormone (FSH). After ovulation has occurred, IGF-2 promotes progesterone secretion during the luteal phase of the menstrual cycle together with Luteinizing Hormone (LH). Thus, IGF2 acts as a Co-hormone together with both FSH and LH. IGF-2 may play a key role in memory and could potentially be used to treat Alzheimer's Disease. It is sometimes produced in excess in islet cell tumours, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. has been shown to interact with IGFBP3 and Transferrin.

Molecular Weight: 35.3 kDa

Gene ID: 18, 17

Pathways: Hormone Activity, Regulation of Hormone Metabolic Process, Regulation of Hormone Biosynthetic Process, Regulation of Carbohydrate Metabolic Process, Activated T Cell Proliferation